The addition of pembrolizumab to gemcitabine and cisplatin conferred a statistically significant and clinically meaningful survival benefit for patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 study.
“We were encouraged to see the consistency of benefit across geographic regions, including non-Asian regions, and across PD-L1 expression subgroups,” Robin “Katie” Kelley, MD, professor of clinical medicine at Helen Diller Family Comprehensive Cancer Center at University of California, San Francisco, told Healio.
Kelley presented the